key: cord-0837163-jz6mg4ju
authors: Santos, Renata Emmanuele Assunção; da Silva, Maria Giselda; do Monte Silva, Maria Caroline Barbosa; Barbosa, Danielly Alves Mendes; Gomes, Ana Lisa do Vale; Galindo, Ligia Cristina Monteiro; da Silva Aragão, Raquel; Ferraz-Pereira, Kelli Nogueira
title: Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: A systematic review
date: 2021-01-06
journal: Am J Otolaryngol
DOI: 10.1016/j.amjoto.2020.102889
sha: 6ae6e52be713c9c02133aba411a8353642094062
doc_id: 837163
cord_uid: jz6mg4ju

OBJECTIVE: The aim of the study was to conduct a systematic review of the literature to investigate the time of onset and duration of symptoms of loss of smell and taste in patients diagnosed with COVID-19. METHODS: Two independent authors performed a systematic review of the Medline/PubMed, SCOPUS, COCHRANE, Lilacs and Web of Science electronic databases. The time of onset and duration of symptoms were considered primary outcomes. The sex and age of individuals, the geographical location of the study, the prevalence of symptoms, other associated symptoms, associated comorbidities, and the impact on quality of life and eating habits were considered secondary outcomes. RESULTS: Our search generated 17 articles. Many of the studies reported that the onset of anosmia and ageusia occurred 4 to 5 days after the manifestation of other symptoms of the infection and that these symptoms started to disappear after one week, with more significant improvements in the first two weeks. CONCLUSION: The present study concludes that the onset of symptoms of loss of smell and taste, associated with COVID-19, occurs 4 to 5 days after other symptoms, and that these symptoms last from 7 to 14 days. Findings, however, varied and there is therefore a need for further studies to clarify the occurrence of these symptoms. This would help to provide early diagnosis and reduce contagion by the virus.

COVID-19 (Coronavirus 2019 disease), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first registered in China in December 2019, being associated with severe acute respiratory syndrome [1] . The spread of the virus was very rapid, reaching pandemic status in early 2020 [2] . By the end of August 2020, the World Health Organization (WHO) had registered 24,021,218 confirmed cases and 821,462 confirmed deaths [3] . Brazil was the first country in Latin America to diagnose a patient with COVID-19, on February 25, 2020, in the city of São Paulo. According to the WHO, by the end of August 2020, Brazil had registered 3,669,995 confirmed cases and 116,580 deaths [3] .

The most prevalent symptoms in the first patients included fever, cough, myalgia and shortness of breath [4] . However, as the pandemic spread to more countries and the numbers of infected individuals increased, other signs and symptoms came to be viewed as clinical manifestations of the disease [5] . One unusual symptom in particular began to appear in an increasing number of patients: dysfunction of smell and taste -loss of sensitivity to taste and smell [6] . In South Korea, China and Italy, a large percentage of infected patients developed anosmia or hyposnomy [4] . In Italy, about 33.9% of patients reported changes in smell and taste and 11% reported both disorders [6] . In South Korea, where tests were performed on a large scale, 30% of patients had loss of smell as the main sign in mild cases of infection [4] . More than two-thirds of those infected in Germany developed anosmia [4] . In Brazil, a study carried out with 253 recovered patients, showed that 212 had experienced sudden-onset anosmia and 196 had developed loss of smell accompanied by nonspecific inflammatory symptoms [6] . Sudden changes in smell thus came to be seen as initial signs of COVID-19 [7] and, anosmia, in the absence of other symptoms, such as rhinorrhea or nasal congestion, may be an indicator of SARS-CoV-2 infection [8] [9] [10] [11] [12] .

In view of this, the Center for Disease Control and Prevention (CDC) added the loss of taste and smell to the list of signs and symptoms that may arise from the second to the fourteenth day after exposure to the virus. During this time, there are generally no specific clinical manifestations, because it is the viral incubation period [1] . The Brazilian Academy of Rhinology and the Brazilian Association of Otorhinolaryngology and Cervical-Facial Surgery duly issued a warning that cases of anosmia, with or without concomitant ageusia, may indicate the presence of infection by COVID-19 [6] . However, despite being a very prevalent symptom in patients with COVID-19, the onset time and duration of these symptoms has not been well established. Understanding of this issue would contribute greatly to early diagnosis, thereby enabling prevention of further contagions and possible complications. We thus performed a systematic review of the literature to investigate the time of onset and duration of symptoms of loss of smell and taste in patients diagnosed with COVID-19.

The present systematic review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [13] . Our review was conducted using a protocol submitted to the International Prospective Registry for Systematic Reviews (PROSPERO) and published under registration number: CRD42020186114.

The literature search was carried out in May 2020 using the Medline/ PubMed (Online System for Research and Analysis of Medical Literature), SCOPUS, COCHRANE, Lilacs (Latin American and Caribbean literature in health sciences) and Web of Science electronic databases. Variations of the following descriptors were used: COVID-19; SARS-COV-2; smell; taste; olfaction disorders; anosmia; taste disorders; dysgeusia.

The bibliographic search in the electronic databases was carried out by two independent reviewers (SANTOS REA and DA SILVA, MG), using a pre-established protocol. A third reviewer (BARBOSA, DAM) was consulted when necessary and acted as a mediator in decisions regarding inclusion or exclusion criteria, on occasions when there was no agreement between the reviewers. Data extraction was performed according to the eligibility criteria established for the study.

The present review included human studies that assessed the symptoms of loss of smell and/or taste in patients diagnosed with COVID-19, regardless of laboratory confirmation and other symptoms related to the disease. Studies were excluded if they did not explain in detail the outcomes investigated in the present review or if they did not provide detailed explanation of their methodology. Case-reports, letters to the editor, literature reviews, systematic reviews, meta-analyses, and in vitro and animal studies were also excluded. There were no restrictions regarding language or year of publication.

The assessment of the risk of bias in the studies was performed independently by two reviewers using the Modified Health Care Research and Quality Agency (AHRQ) instrument [14] . The studies were evaluated using a list of twenty-six items, divided into nine evaluation criteria: study question, study population, subject comparability, exposure or intervention, measured results, statistical analysis, results, discussion, and funding or sponsorship [14, 15] .

The primary outcomes for reviewing the literature on loss of smell and taste in patients diagnosed with COVID-19 were the time of onset and duration of symptoms. Secondary outcomes included the sex and age of individuals, the geographical location of the study, prevalence of symptoms, other associated symptoms, associated co-morbidities, and the impact on quality of life and eating habits.

The level of agreement between the reviewers and the quality of the studies (risk of bias) were analyzed using the kappa coefficient on the Statistical Package for the Social Sciences -SPSS version 20 for Windows (IBM SPSS Software, Armonk, NY, USA).

The initial database search identified a total of 298 articles, 122 in Medline/PubMed, 157 in Scopus, one in LILACS, 18 in Web of Science and none in Cochrane. Removal of duplicate articles reduced the total to 200, which title and abstract screening reduced further to 22 articles. These 22 studies underwent full-text analysis, resulting in the exclusion of 5 studies and generating a final total of 17 articles included for analysis, as shown in the flowchart presented in Fig. 1 . Table 1 shows the evaluation of the articles according to the points highlighted by West [14] . Evaluation of quality criteria revealed methodological shortcomings in some articles, including: failure to justify the sample size (all articles included in the review); failure to detail inclusion and exclusion criteria [8, 9, 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] ; analysis of individuals who were not tested for COVID-19 [18] [19] [20] [21] ; failure to address the limitations of the study [15, 21] ; and failure to cite sources of financing, even if these did not exist [8, 10, 15, 19, 20, [24] [25] [26] [27] . The level of agreement between reviewers regarding analysis of data extraction and risk of bias was almost perfect (Kappa: 0.8824) [28] .

The results of studies of the time of onset and duration of symptoms of loss of smell and taste in patients diagnosed with COVID-19, as well as the sex and age of individuals, the geographical location of the study, the prevalence of symptoms, associated symptoms, associated comorbidities, and the impact on quality of life and eating habits, are summarized in Table 2 .

All 17 articles provided data on the age and sex of individuals, although only five articles found an association between sex and alterations in the sense of taste or smell [10, 12, 15, 24, 25] , with women presenting a higher prevalence of such alterations. Only four articles found an association between age and olfactory and gustatory symptoms, [10, 15, 24, 25] , although these results were inconsistent. Two studies found that younger people presented a higher prevalence of these symptoms [10, 25] ; one study found that adults with a mean age of 36.5 were more affected [24] ; and one study showed that symptoms were more prevalent in individuals over 50 years of age [15] .

The studies covered by the present review provided data for countries on three continents, three articles were from Asia [21, 23, 24] , five from North America [9, 16, 17, 20, 22] , and 10 from Europe [8] [9] [10] 12, 15, 18, 19, [25] [26] [27] . All articles reported alterations in the sense of smell and taste in patients with COVID-19, although, in Asian countries, the prevalence of olfactory and gustatory dysfunction reported was lower compared to North America and Europe. In China, the prevalence of such symptoms was 5.6%, in Korea, 15%, and, in Singapore, 22%. In North America and Europe, the prevalence varied from 18.6% to 90%.

The articles reviewed reported conflicting results regarding the time of onset of symptoms of loss of smell and/or taste in patients diagnosed with COVID-19. Many studies, however, reported that the onset of anosmia and ageusia occurred 4 to 5 days after the appearance of other symptoms of the infection [15, 26, 27] . Analysis of the prevalence of the appearance of changes in smell and/or taste before, simultaneously with or after other symptoms as reported in these articles found that the prevalence of such symptoms emerging prior to other symptoms varied between 13% [19] and 73% in patients (before diagnosis) [9] ; the prevalence of such symptoms emerging at the same time as other symptoms, varied from 13.5% [8] to 38.4% [19] ; and that of such symptoms appearing after other symptoms from 27% [9] to 48.6% [19] .

The duration of symptoms of loss of smell and/or taste in patients diagnosed with COVID-19 was addressed in eight articles [9, 10, 15, [17] [18] [19] 24, 26] . The findings were inconsistent but, generally speaking, the symptoms begin to disappear after one week [9, 15, 24] , and, in the first two weeks, significant improvement occurred [17] [18] [19] . In addition, two studies found that 34% [15] and 37.5% [10] of the subjects continued to show symptoms for at least 7 days, even after recovery from the disease.

Only one of the studies reviewed did not assess the prevalence of symptoms of loss of smell and/or taste in patients diagnosed with COVID-19. This study looked only at individuals who had already presented with anosmia [9] . Six combined the prevalence for symptoms of loss of smell and taste, reporting a minimum prevalence of 19% [22] and a maximum of 73.6% [15] . Regarding olfactory disorders alone, six studies found a prevalence of over 68% [10, 12, 16, 17, 25, 27] and two found a prevalence of less than 7.27% [23, 24] . In relation to taste disorders, six studies reported a prevalence greater 54.2% [10, 16, 17, 19, 25, 27] and two registered a prevalence of below 5.1% [23, 24] .

Many studies also showed that changes in smell and/or taste may occur concomitantly with other symptoms. The most commonly mentioned were: fever [8, 12, 16, 17, [19] [20] [21] [22] [23] [25] [26] [27] , cough [8, 10, 12, 15, [19] [20] [21] [22] [23] [25] [26] [27] , headache [8, 10, 15, 20, 22, 26, 27] , and fatigue [12, 16, 17, 26] . Some studies also reported gastrointestinal symptoms [8, [15] [16] [17] 20, 22, 26, 27] ., Six studies found that smell and taste disorders occurred together with nasal obstruction [10, 12, 15, 20, 25, 26] . 

Five of the studies covered by our review investigated co-morbidities present in patients diagnosed with COVID-19 [10, 22, 23, 25, 26] . The most prevalent co-morbidities were systemic arterial hypertension [10, 22, 23, 25, 26] , rhinitis [10, 25] , asthma [10, 25, 26] , and cardiovascular disease [22, 23, 26] .

The spread of COVID-19 around the world has been accompanied by the appearance of symptoms that differ from a common flu [29, 30] . Changes in smell and taste have been strongly associated with a positive diagnosis of infection by the new coronavirus [31] . This association is confirmed by the prevalence of more than 50% for anosmia and/or agneusia in patients with COVID-19 [10, 12, 15, 16, 27] . However, the time of onset time and duration of these symptoms has yet to be clearly established. Adequate quantification of loss of smell and/or taste, and identification of the temporal relationship between COVID-19 contagion and olfactory and/or gustatory dysfunctions would provide great assistance in arriving at an early diagnosis and thereby avoiding further contagion and possible complications [32] . The present systematic review thus aimed to establish the time of onset and duration of symptoms of loss of smell and taste in patients diagnosed with COVID-19.

The tool used to assess risk of bias (AHRQ) [14] found that the articles reviewed were effectively addressed the proposed study question. Some, however, were marred by methodological shortcomings, especially with regard to the "study population", since they did not calculate the sample size. However, this probably occurred due to the lack of information on the prevalence of this novel disease. We also observed that the studies analyzed employed a variety of different methods and presented their findings in different ways, making it impossible to carry out a meta-analysis.

All articles included in this review investigated both female and male individuals, but only five articles found any association between sex and changes in taste and smell [10, 12, 15, 24, 25] . Although men have a less favorable prognosis for COVID-19 [33] , the prevalence in women of changes in smell and taste was higher in the five studies reviewed [10, 12, 15, 24, 25] . The average age range was 38 to 65 years, with a predominance of adults and elderly people affected by the infection. This is the age group that appears to be most affected by COVID-19 [34] [35] [36] . One study cited working outside the home during the pandemic as an important risk factor for the transmission of the disease among adults, as this occasions more contact with people and, consequently, greater exposure to the virus [37] .

The prevalence of smell and taste dysfunction appeared to be lower in Asia, compared to North America and Europe. It is thus possible to identify a change in the profile of the main symptoms as the disease passes through different countries. This may be related to the different strains of the virus that have been circulating since the beginning of the COVID-19 pandemic. Around 93 mutations have been observed throughout the SARS-CoV-2 genome in different geographic regions [38] . A meta-analysis carried out with cases of COVID-19 in China, the country that presented the first cases of the disease, showed that the main symptoms were fever, cough, fatigue, sputum and dyspnea [39] . When the disease reached European countries, a change in symptoms occurred and olfactory and gustatory changes began to appear as clinical signs. Such signs may prove a great aid to diagnosis of COVID-19, since they are predominant symptoms in people affected by the virus [40] . Most patients with Sars-CoV-2 infection are considered asymptomatic and do not require hospitalization [10] . Symptomatic patients have symptoms such as fever, dry cough, shortness of breath, gastrointestinal symptoms and also symptoms that mainly affect smell and taste, in which there is a significant reduction in these senses. Such symptoms Table 1 Characterization of studies according to evaluation criteria highlighted by West et al. (2002) . -Adult patients, diagnosed or not with COVID-19, reported their symptoms, focusing on smell and taste, by way of an internet platform (Qualtrics, Provo, UT). The sample was divided into "COVID positive" and "COVID negative" patients. A comparison was made between these two groups. -Input data from the "COVID-19 Anosmia Report to Clinicians" was analyzed. This tool enables health professionals to submit a confidential report of cases of anosmia and dysgeusia related to COVID 19. 3. 47% of individuals diagnosed with COVID 19 had anosmia. Of these, 85% also had dysgeusia. 4. Anosmia was associated with dysgeusia 85%; rhinorrhea (57%); nasal obstruction (30%); fatigue (93%); cough (87%); headache (82%); fever (74%); myalgia (74%); arthralgia (72%) and diarrhea (52%). 5. The most frequent comorbidities were: asthma (13%), high blood pressure (13%) and cardiovascular diseases (11%). Mao et al., 2020 214 adults were studied, 127 women and 87 men. The average age was 52.7 years. The study was conducted in Wuhan, China.

-Data were collected from January 16, 2020 to February 19, 2020 at three special service centers designated for COVID-19 in China.

-Clinical data were extracted from electronic medical records and data on all neurological symptoms and verified by two trained neurologists. have been reported mainly in countries in Europe and America [25] .

In the studies evaluated the prevalence of changes in both taste and smell in patients with COVID-19 ranged from 19% to 73%. Furthermore, a survey of 204 patients found a prevalence of these symptoms of 56.9% among adults [41] . Another study found that 19% of patients experienced loss of both olfactory and gustatory functions concomitantly [42] . Even with these divergences, the presence of the two associated symptoms in individuals with suspected COVID-19 is of great importance for the diagnosis of this infection, It can, in fact, be seen from the articles included in this review that, in patients with a positive or negative diagnosis, these changes in smell and taste were more likely to be present in patients with a positive diagnosis of the disease. This association has also been observed in other studies of adult individuals with a positive diagnosis of COVID-19 [42, 43] .

Regarding the time of onset of smell and/or taste changes in patients with COVID-19, it was difficult to establish a relationship between the findings of the studies reviewed, because of the extent to which they differ from one another. Some of the authors indicate that these changes may precede the development of other common symptoms of the disease, such as fever, shortness of breath, dry cough and fatigue [8, 10, 12] . It is important to note that, in the context of a pandemic, tracking symptoms of loss of smell and/or taste in non-hospitalized patients may prove to be a useful clinical screening tool [15] , helping to direct patients towards testing services and thus helping to commence care early on and hence reduce transmission of the disease.

The results of the studies also diverged regarding the duration of symptoms of loss of smell and/or taste. This ranged from five days to four weeks, with an average of one to two weeks for recovery. In addition, a case-control study with 119 individuals found that the average duration of smell and/or taste disorders was 7.5 ± 3.2 days, and that 40% of individuals recovered completely 7.4 ± 2.3 days after the onset of symptoms, without having to seek hospital care [31] . More detailed investigation of the duration of these symptoms is, however, still required. Two of the studies reviewed reported persistence of symptoms, even after recovery from the disease [10, 15] . Furthermore, the impact of this persistence of olfactory and gustatory loss after the end of COVD-19 infection is still unclear. We therefore stress the importance of conducting research that analyzes the time and persistence of symptoms associated with olfactory and gustatory disorders in patients with COVID-19, since the results found in the literature are scarce and present divergent findings.

The scientific literature considers a number of hypotheses regarding the pathogenic mechanisms associated with changes in smell and taste in patients with COVID-19 and some of these takes into account the duration of sensory dysfunctions. One such hypothesis is that these disorders occur due to direct damage caused by the virus to olfactory and gustatory receptors [44] . It is believed that changes in smell can be caused by damage caused by the virus to the olfactory bulb [44] , or to the olfactory nerve [24] . In the case of taste disorders, studies have hypothesized that this may be associated with damage to the angiotensin-converting enzyme 2 (ACE2) [15] , which was recently identified as the SARS-CoV-2 cell receptor [45] . ACE2 receptors are present in the oral cavity [46] and have been associated with the modulation of taste perception [46] . Furthermore, Cazzolla et al. [47] have observed a correlation between the occurrence of smell and taste disorders and IL-6 levels. Recovery of olfactory and gustatory functions is associated with reduced levels of IL-6 and one probable explanation for this finding concerns the role that IL-6 plays at the peripheral level in cell receptors infected by the virus. At the central level, IL-6 also plays a role in the intermediate stages on the gustatory and olfactory pathways, especially in the thalamus [47] . Further studies, however, are needed to shed light on the physiological mechanisms associated with these symptoms, both in cases where changes in smell and/or taste are transient and in those where they are permanent.

It was also observed that changes in smell and/or taste may occur concomitantly with other symptoms. The other symptoms most commonly mentioned by the studies under review were: fever, cough, headache, fatigue and gastrointestinal symptoms. These are classic symptoms of the mildest form of COVID-19. The literature indicates that the most severe symptoms of the virus include respiratory distress, fever, cough and fatigue [39, 48] . Other, less prevalent symptoms that may appear are diarrhea, nausea and vomiting [49, 50] . Of the thirteen studies, only six reported individuals presenting changes in smell and taste who also experienced nasal obstruction [10, 12, 15, 20, 25, 26] . This corroborates case reports showing that anosmia and ageusia can be found in patients testing positive for COVID-19, even when other respiratory symptoms are absent [29, 50] . Vaira et al. [44] thus claim that sudden changes in smell and taste, usually not accompanied by symptoms of nasal obstruction or rhinitis, are strongly suggestive of ongoing COVID-19 infection and should be treated with care. The most prevalent comorbidities in individuals with COVID-19 experiencing loss of smell and/or taste were: systemic arterial hypertension [10, 16, [24] [25] [26] , rhinitis [10, 25] , asthma [10, 25, 26] and cardiovascular diseases [16, 24, 26] . Furthermore, Chen et al. compared the characteristics of patients diagnosed with COVID-19 who died with those who recovered, and observed that those who died were more likely to have a comorbidity, such as hypertension, diabetes, cardiovascular disease or chronic lung disease [51] . No study mentioned the impact of smell and/or taste dysfunction on the quality of life and eating habits of patients with COVID-19.

Taste and smell play an important role in the selection of diet, metabolism, and quality of life. Anosmic individuals may present changes in eating habits, such as increased seasoning and use of sugar [52] . In addition, increased consumption of salt, sugar, and fat in patients with changes in smell or taste may complicate issues relating to hypertension, diabetes and cardiovascular diseases [53] . A longitudinal cohort study with subjects self-reporting impaired sense of taste and smell showed these individuals to have greater increases in systolic blood pressure and mean arterial pressure compared to individuals without impaired taste and smell [54] . In view of the high prevalence of co-morbidities such as arterial hypertension and cardiovascular diseases associated with dysfunctions of smell and/or taste in patients diagnosed with COVID-19, studies are therefore needed to investigate the influence of changes in smell and/or taste on quality of life and eating habits in patients diagnosed with COVID-19, especially those with co-morbidities such as hypertension, diabetes, obesity, cardiovascular disease, and others.

The main limitation of the present study was the heterogeneity of the selected articles, which employed a variety of different methodologies. Some used virtual questionnaires, while others used the medical records of hospitalized patients or telephone interviews. These factors may have influenced the findings regarding the exact duration of olfactory and gustatory symptoms, since most of the studies were based on patient reports and conducted with no prior explanation as to what these symptoms are or how they may change over time. This may lead to a lack of accurate information regarding the reported symptoms.

The present study concluded that the onset of symptoms of loss of smell and taste, associated with COVID-19, was 4 to 5 days after other symptoms, and that these symptoms lasted from 7 to 14 days. Findings, however, varied and there is therefore a need for further studies to clarify the occurrence of these symptoms. This would help to provide early diagnosis and reduce contagion by the virus. Furthermore, loss of the sense of smell and taste, in the absence of symptoms indicative of nasal obstruction, to provide a strong indication for a diagnosis of COVID-19. We should also note the need for nutritional monitoring of patients with olfactory and gustatory changes, to avoid excessive consumption of salt and sugar. Finally, it is recommended that a molecular diagnostic test for SARS-CoV-2 be performed in all individuals with sudden, severe loss of smell and taste, and no other symptoms.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

KNFP conceptualized and designed the study, drafted, and critically revised the manuscript. REAS, MGS, MCBMS, and DAMB performed literature reviews, critically reviewed, interpreted data/literature reviews, drafted, and revised the manuscript. ALVG, LCMG and RSA conceptualized and designed the study, critically reviewed the manuscript draft and revisions.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and metaanalysis. Otolaryngol -Head Neck Surg (United States) 2020

Pandemic fear"' and COVID-19: mental health burden and strategies

WHO coronavirus disease (COVID-19) dashboard

Otorhinolaryngologists and coronavirus disease 2019 (COVID-19)

Ageusia and anosmia, a common sign of COVID-19? A case series from four countries

Incomplete and late recovery of sudden olfactory dysfunction in COVID-19

The diagnostic value of detecting sudden smell loss among asymptomatic COVID-19 patients in early stage: the possible early sign of COVID-19

Selfreported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study

COVID-19 anosmia reporting tool: initial findings. Otolaryngol -Head Neck Surg (United States) 2020

Clinical and epidemiological characteristics of 1,420 European patients with mildto-moderate coronavirus disease 2019

More than smell -COVID-19 is associated with severe impairment of smell, taste, and chemesthesis

Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Systems to rate the strength of scientific evidence

Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

Self-reported olfactory loss associates with outpatient clinical course in COVID-19

Early recovery following new onset anosmia during the COVID-19 pandemic -an observational cohort study

Presentation of new onset anosmia during the covid-19 pandemic

Smell and taste symptombased predictive model for COVID-19 diagnosis

The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19. Eur Arch Oto-Rhino-Laryngology

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Prevalence and duration of acute loss of smell or taste in COVID-19 patients

Olfactory and gustatory dysfunctions as a clinical presentation of mild-tomoderate forms of the coronavirus disease (COVID-19): a multicenter European study

Features of anosmia in COVID-19

Olfactory and gustatory dysfunction in coronavirus disease 19 (COVID-19)

An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers

Anosmia and dysgeusia in the absence of other respiratory diseases: should COVID-19 infection be considered?

Anosmia and ageusia are emerging as symptoms in patients with COVID-19: what does the current evidence say? Ecancermedicalscience

Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study

The loss of smell and taste in the COVID-19 outbreak: a tale of many countries

Sex difference and smoking predisposition in patients with COVID-19

Severe obesity is associated with higher in-hospital mortality in a cohort of patients with COVID-19 in the Bronx

Risk of death by age and gender from CoVID-19 in Peru

A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period

Covid-19: prevention and control measures in community

Genetic diversity and evolution of SARS-CoV-2

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of metaanalysis

A new symptom of COVID-19: loss of taste and smell

Prevalence of taste and smell dysfunction in coronavirus disease 2019

Olfactory dysfunction in the COVID-19 outbreak

Taste and smell impairment in COVID-19: an AAO-HNS anosmia reporting tool-based comparative study. Otolaryngol -Head Neck Surg (United States) 2020

Potential pathogenesis of ageusia and anosmia in COVID-19 patients

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The influence of hypotensive drugs on the taste sensitivity in patients with primary hypertension

Taste and smell disorders in COVID-19 patients: role of interleukin-6

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and metaanalysis

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Anosmia and ageusia as the only indicators of coronavirus disease 2019 (COVID-19)

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Anosmia and nutritional status

Nutrition and taste and smell dysfunction

A longitudinal study of altered taste and smell perception and change in blood pressure

We are thankful to NPlast (the Phenotypic Nutrition and Plasticity Studies Unit) for technical support. This study received financial assistance from the Coordination for the Improvement of Higher Education Personnel (CAPES -Brazil), the National Council for Scientific and Technological Development (CNPq -Brazil), the Pro-Rectory for Research and Innovation (Propesqi -UFPE), and the Foundation for the Support of Science and Technology of Pernambuco (FACEPE -Brazil). The study sponsors were not involved in the study design; data collection, analysis, and interpretation; the writing of the manuscript; nor in the decision to submit the manuscript for publication.